Showing results (141-150 of 165) with videos related to

Sort By:
Pageof 17
Journal of Medical Virology|September 19, 2022
Anti-SARS-CoV-2 activity of targeted kinase inhibitors: Repurposing clinically available drugs for COVID-19 therapyRuthMabel Boytz, Mikołaj Słabicki, Sita Ramaswamy, et al.
Molecular Therapy. Oncology|April 15, 2025
Erratum: Dual CARM1-and IKZF3-targeting: A novel approach to multiple myeloma therapyWei Ni, Swati Garg, Basudev Chowdhury, et al.
Cell Reports. Medicine|June 16, 2026
The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided careAritro Nath, Jyoti Malhotra, Isa Mambetsariev, et al.
Leukemia|July 30, 2021
Small molecule inhibition of deubiquitinating enzyme JOSD1 as a novel targeted therapy for leukemias with mutant JAK2Jing Yang, Ellen L Weisberg, Xiaoxi Liu, et al.
Leukemia|May 19, 2021
JunB is a key regulator of multiple myeloma bone marrow angiogenesisFengjuan Fan, Stefano Malvestiti, Sonia Vallet, et al.
Molecular Cancer Therapeutics|July 25, 2015
Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097Ellen Weisberg, Ensar Halilovic, Vesselina G Cooke, et al.
Plos One|February 4, 2010
CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinasesYi-Hung Carol Tan, Soundararajan Krishnaswamy, Suvobroto Nandi, et al.
Molecular Cancer Therapeutics|July 13, 2021
Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung CancerTamara Mirzapoiazova, Gang Xiao, Bolot Mambetsariev, et al.
Nature Medicine|May 13, 2014
Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancersFrancesca Cottini, Teru Hideshima, Chunxiao Xu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2009
Ethnic differences and functional analysis of MET mutations in lung cancerSoundararajan Krishnaswamy, Rajani Kanteti, Jonathan S Duke-Cohan, et al.
Pageof 17